Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 CAD | +2.17% | +1.44% | -21.23% |
Mar. 08 | RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating | MT |
Mar. 07 | Transcript : Oncolytics Biotech Inc., Q4 2023 Earnings Call, Mar 07, 2024 |
Evolution of the average Target Price on Oncolytics Biotech Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Oncolytics Biotech Inc.
HC Wainwright | |
JonesTrading Institutional Services | |
Canaccord Genuity | |
Maxim | |
RBC Capital Markets |
EPS Revisions
- Stock
- Equities
- Stock Oncolytics Biotech Inc. - Toronto S.E.
- Consensus Oncolytics Biotech Inc.